000 01667nam  2200361zi 4500
0019.894041
003CaOODSP
00520221107173624
006m     o  d f      
007cr |||||||||||
008201126t20202020onc     ob   f00| 0 eng d
020 |a9780660367521
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH14-355/2020E-PDF
24500|aGuidance for market authorization requirements for COVID-19 vaccines.
264 1|a[Ottawa] : |bHealth Canada = Santé Canada,|c2020.
264 4|c©2020
300 |a1 online resource (15 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Ligne directrice sur les exigences relatives aux autorisations de mise en marché des vaccins contre la COVID-19.
500 |aIssued also in HTML format.
504 |aIncludes bibliographical references (pages 13-15).
650 0|aCOVID-19 (Disease)|xVaccination|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tLigne directrice sur les exigences relatives aux autorisations de mise en marché des vaccins contre la COVID-19.|w(CaOODSP)9.894043
794 |tGuidance for market authorization requirements for COVID-19 vaccines.|w(CaOODSP)9.898409
85640|qPDF|s766 KB|uhttps://publications.gc.ca/collections/collection_2021/sc-hc/H14-355-2020-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/guidance-market-authorization-vaccines.html